In re HIV Antitrust Litigation

CourtDistrict Court, N.D. California
DecidedApril 18, 2023
Docket3:19-cv-02573
StatusUnknown

This text of In re HIV Antitrust Litigation (In re HIV Antitrust Litigation) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re HIV Antitrust Litigation, (N.D. Cal. 2023).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 IN RE HIV ANTITRUST LITIGATION. Case No. 19-cv-02573-EMC

8 ORDER RE PASS-ON DEFENSE AND 9 DUPLICATIVE RECOVERY DEFENSE 10 Docket Nos. 1727, 1729-2 11

12 13 14 In the Court’s order on in limine motions, it deferred ruling on several issues. Two issues 15 that it deferred ruling on arose from Plaintiffs’ Motion in Limine No. 6. The two issues are: (1) 16 whether Defendants should be barred from introducing evidence that Plaintiffs “passed on” any 17 overcharge to someone else; and (2) whether Defendants should be barred from arguing that there 18 should not be duplicative direct purchaser and indirect purchaser recovery. 19 The parties have filed supplemental briefs on these two issues. See Docket Nos. 1727, 20 1729-2. The Court notes that the only Plaintiffs who have a stake here are the indirect purchasers 21 – i.e., the EPPs, the IHPPs, and United.1 The Court uses the term “Plaintiffs” in this order to refer 22 to only the indirect purchasers. 23 I. DISCUSSION 24 A. Pass-On Defense 25 According to Plaintiffs, Defendants do not have a viable pass-on defense because Plaintiffs 26

27 1 United has a stake only to the extent the Court were to hold that its claims are governed by the 1 (as TPPs) are at the end of the distribution chain – i.e., there is no one else for them to pass any 2 overcharge on to. In response, Defendants take the position that Plaintiffs did pass on overcharges

3 in the form of higher premiums . . . . According to their witness list, the EPPs, United, and IHPPs may present live fact testimony from 4 11 plaintiff representatives regarding indirect purchases. Defendants are entitled to examine those witnesses as to Plaintiffs’ 5 policies and procedures for setting premiums and passing on costs. 6 Defs.’ Br. at 7-8. 7 Courts have disagreed as to whether an antitrust defendant can claim a pass-on of an 8 overcharge via a premium. Most courts have sided with Plaintiffs. The main reasoning is that

9 insurance premiums are not a pass on of alleged overcharges because premiums are set by anticipating future projected costs, not 10 to recover money that insurers paid in the past. Moreover, there is no evidence that the defendants would be able to ascertain how the 11 pricing of [the] Products [at issue] affected premiums or the financial status of the EPPs, since EPPs reimburse prescriptions for 12 thousands – if not tens of thousands – of different drugs and dosages. Thus, even ignoring the fact that the overwhelming 13 majority of factors that go into setting contribution rates and premiums have nothing to do with drug prices[,] the defendants 14 would not be able to ascertain the effect of the [the] Products' prices by analyzing premiums or the EPPs' financial status. 15 16 In re Asacol Antitrust Litig., No. 15-12730-DJC, 2017 U.S. Dist. LEXIS 952, at *17-18 (D. Mass. 17 Jan. 4, 2017) (internal quotation marks omitted). 18 The Court finds the above reasoning persuasive. In addition to the difficulty of allocating 19 the effect on prices, there is no evidence that premiums are backward looking, instead of forward 20 looking, and hence they are not relevant to the assessment of damages. Another problem for 21 Defendants is that, as Plaintiffs point out, Defendants’ own expert (Dr. Jena) does not appear to 22 have proposed a specific adjustment to make based on this pass-on theory. 23 Defendants have suggested that they are still entitled to ask fact witnesses about passing 24 on. As noted above, Defendants state: “According to their witness list, the EPPs, United, and 25 IHPPs may present live fact testimony from 11 plaintiff representatives regarding indirect 26 purchases. Defendants are entitled to examine those witnesses as to Plaintiffs’ policies and 27 procedures for setting premiums and passing on costs.” Defs.’ Br. at 7-8. But Defendants have 1 if the fact witnesses were to testify that prescription drug costs are taken into account in setting 2 premiums, Defendants have failed to make any showing as to how it would not be speculative for 3 these fact witnesses to talk about and quantify passing on overcharges for Truvada and Atripla 4 specifically. The jury would have to speculate as to how much to deduct from damages in order to 5 account for this claimed passing on. 6 Accordingly, the Court rejects Defendants’ attempt to argue that they are entitled to a 7 passing-on defense because TPPs purportedly passed on overcharges via premiums. 8 B. Duplicative Recovery/Offset Defense 9 The next issue for the Court to consider is whether Defendants should be barred from 10 arguing that there should not be duplicative direct purchaser and indirect purchaser recovery. 11 Defendants assert that there are 13 jurisdictions that “either prohibit or limit potential damages to 12 indirect purchasers where direct purchasers also seek damages for the same injury.” Defs.’ Br. at 13 2. Those jurisdictions are: 14 (1) D.C. 15 (2) Hawaii. 16 (3) Illinois. 17 (4) Maine. 18 (5) Minnesota. 19 (6) Nebraska. 20 (7) New Mexico. 21 (8) New York. 22 (9) Rhode Island. 23 (10) South Dakota. 24 (11) Utah. 25 (12) Vermont. 26 (13) Wisconsin. 27 See Defs.’ Br. at 2. Defendants contend that 6 of the 13 jurisdictions require that there be an offset 1 decision.2 2 Plaintiffs initially assert that the Court should not consider Defendants’ argument because 3 it was not timely made. See Pls.’ Br. at 4 (arguing that “it is too late for Defendants to raise this 4 issue” because, e.g., “[t]hey did not include any such set-off in any of the pretrial filings (proposed 5 jury instructions, verdict form, pre-trial memorandum, etc.), including in their MIL 6 opposition, 6 which merely cited the Utah statute referencing such a possibility”; “[n]or have they offered any 7 expert testimony as to how an offset would work”). The Court rejects this contention. 8 Defendants’ position was timely raised in the opposition to Plaintiffs’ Motion in Limine No. 6. 9 On the merits, Plaintiffs’ main argument in response is that the state statutes identified by 10 Defendants are concerned about duplicative recovery only where both the direct purchaser and the 11 indirect purchaser are suing under state law. In other words, Plaintiffs take the position that, 12 where a direct purchaser sues under federal law, and the indirect purchaser sues under state law, 13 the state law provisions addressing duplicative recovery are not implicated. Plaintiffs contend that 14 this must be the case because, otherwise, an indirect purchaser could never recover anything under 15 state law since the direct purchaser, under federal law, would be entitled to claim the entire 16 overcharge regardless of any pass-on. Plaintiffs maintain:

17 To interpret any of those state laws to apply where direct purchasers assert a federal claim would effectively negate the purpose of the 18 repealer statute, denying the remedy to indirect purchasers the states expressly provide by law. More pointedly, if a set off defense or 19 apportionment under state law allows or requires direct purchaser damages obtained on a federal claim to be offset against indirect 20 purchaser damages, any adjustment to avoid duplicative recoveries could effectively wipe out indirect purchaser damages. 21 22 Pls.’ Br. at 6; cf. In re Flash Memory Antitrust Litig., 643 F. Supp. 2d 1133, 1156 (N.D. Cal. 2009) 23 (“‘States . . . which have repealed Illinois Brick and allowed indirect purchasers to sue for antitrust 24 violations, have necessarily made the policy decision that duplicative recovery may permissibly 25 occur. Duplicative recovery is, in many if not all cases alleging a nationwide conspiracy with both 26 direct and indirect purchaser classes, a necessary consequence that flows from indirect purchaser 27 1 recovery.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re New Motor Vehicles Can. Export Anti. Lit.
522 F.3d 6 (First Circuit, 2008)
In Re Flash Memory Antitrust Litigation
643 F. Supp. 2d 1133 (N.D. California, 2009)
McKinnon v. Honeywell International, Inc.
2009 ME 69 (Supreme Judicial Court of Maine, 2009)
Apple, Inc. v. Pepper
587 U.S. 273 (Supreme Court, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
In re HIV Antitrust Litigation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-hiv-antitrust-litigation-cand-2023.